The CEO said the phase three OPERO1 monotherapy trial of palizestrant in the second, third-line setting reads out in Q1. Phase two data showed median PFS of 7.3 months in ESR1 mutant patients and 5.5 months in ESR1 wild-type patients. The trial assesses both ESR1 mutant and wild-type patients as individual endpoints.
OLMA · Olema Oncology, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As a result, these conditions raise substantial doubt about our ability to continue as a going concern over the long term.”View the 10-Q filed Nov 10, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 67%
- Last earnings
- May 26, 2026
- Latest filing
- 10-Q · Nov 10
- Price history
- Nov 2020 to Nov 2026
Up next
Latest documents
Olema Oncology, Inc. changed its name from Olema Pharmaceuticals, Inc. effective November 12, 2026. It also relocated its principal executive offices to 365 Oyster Point Blvd., Suite 400, South San Francisco, California 94080.
Olima Oncology expects an Opera 01 readout in Q1, said Opera 2 is enrolling “extremely robustly,” and reported $414 million cash, with a possible mid-year 2028 launch.
Olema expects Phase III topline results in Q1 of next year, including ESR-1 mutant and ESR-1 wild type subsets; cash on hand of about $414 million provides runway into 2028.
Olema reported a $189.9 million net loss for the nine months ended September 30, 2026. Palazestrant’s Phase 3 OPERA-01 top-line results are expected in the first quarter of 2027, followed by an NDA submission in 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, and marketable securities | $413.8M | September 30, 2026 | — |
| Non-GAAP G&A expenses non-GAAP | $5.5M | quarter ended September 30, 2026 | — |
|
|
|||
| Non-GAAP R&D expenses non-GAAP | $59.9M | quarter ended September 30, 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OLMA
this stock
Olema Oncology, Inc.
|
$615.00M | -71.9% | — | — | 19.5% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 27
The CEO said the phase three OPERO1 monotherapy trial of palizestrant in the second, third-line setting reads out in Q1. Phase two data showed median PFS of 7.3 months in ESR1 mutant patients and 5.5 months in ESR1 wild-type patients. The trial assesses both ESR1 mutant and wild-type patients as individual endpoints.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OLMA | -7.1% | +9.5% | -34.3% | +0.3% | -71.9% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +1.4% | +18.8% | -25.2% | +9.0% | -73.1% |